Breaking News

Merck KGaA, Maker of Erbitux Cancer Drug, to Acquire Sigma-Aldrich for $17 Billion
Tweet TWEET

Auxilium Pharmaceuticals to Announce First Quarter 2013 Results and Conduct Conference Call on Monday, April 29, 2013

 Auxilium Pharmaceuticals to Announce First Quarter 2013 Results and Conduct
                  Conference Call on Monday, April 29, 2013

PR Newswire

CHESTERBROOK, Pa., April 25, 2013

CHESTERBROOK, Pa., April 25, 2013 /PRNewswire/ --Auxilium Pharmaceuticals,
Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release
results for the first quarter 2013 on Monday, April 29, 2013 before the
opening of the U.S. financial markets. The Company will also conduct a
conference call that day at 8:30 a.m. ET to discuss results and highlights of
the first quarter. The presentation slides to be used during the call will be
available on the "For Investors" section of the Company's web site under the
"Presentations" tab beginning at 7:00 a.m. ET on Monday, April 29, 2013. A
web cast of the conference call and the presentation slides will be available
on the "For Investors" section of the Company's web site under the "Events"
tab beginning at 8:30 a.m. ET on Monday, April 29, 2013. A question and
answer session will follow the presentation.

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )

Mr. Adrian Adams, Chief Executive Officer and President, will host the
conference call.

Conference call details:
Date:                                    Monday, April 29, 2013
Time:                                   8:30 a.m. ET
Dial-in (U.S.):                         866-515-2913
Dial-in (International):                 617-399-5127
Web cast:                                http://www.auxilium.com
Passcode:                               AUXILIUM
To access an audio replay of the call:
Access number (U.S.):                   888-286-8010
Access number (International):          617-801-6888
Replay Passcode #:                       98775073

About Auxilium
Auxilium is a specialty biopharmaceutical company with a focus on developing
and marketing products to predominantly specialist audiences. Auxilium markets
Testim® 1% (testosterone gel) for the topical treatment of hypogonadism and
XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult
Dupuytren's contracture patients with a palpable cord in the U.S.
GlaxoSmithKline LLC co- promotes Testim with Auxilium in the U.S. Ferring
International Center S.A. markets Testim in certain countries of the EU and
Paladin Labs Inc. markets Testim in Canada. Pfizer Inc. has marketing rights
for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46
countries in Eurasia through April 24, 2013; Asahi Kasei Pharma Corporation
has development and commercial rights for XIAFLEX in Japan; and Actelion
Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in
Canada, Australia, Brazil and Mexico. The sBLA for XIAFLEX for the treatment
of Peyronie's disease was submitted to the FDA on November 6, 2012 and has
been accepted for standard review with a PDUFA date of September 6, 2013.
Additionally, collagenase clostridium histolyticum ("CCH") is in phase IIa of
development for the treatment of Frozen Shoulder syndrome (adhesive
capsulitis) and phase Ib of development for the treatment of cellulite
(edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue
additional indications for CCH. For additional information, visit
http://www.auxilium.com.

AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995

This news release contains forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995, including statements made
with respect to Auxilium's strategy, progress and timing of development
programs and related trials, the efficacy of its product candidates, the
commercial benefits available to it as a result of its agreements with third
parties, future operations, financial position, future revenues, projected
costs, prospects, plans and objectives of management and other statements
regarding matters that are not historical facts, and involve predictions.
These statements involve known and unknown risks, uncertainties and other
factors that may cause actual results, performance, achievements or prospects
to be materially different from any future results, performance, achievements
or prospects expressed in or implied by such forward-looking statements. In
some cases you can identify forward-looking statements by terminology such as
''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'',
''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of
these terms or similar expressions, although not all forward-looking
statements contain these identifying words. Although forward-looking
statements are based on Auxilium's current plans or assessments that are
believed to be reasonable as of the date of this press release, they
inherently involve certain risks and uncertainties. These forward-looking
statements are subject to a number of risks and uncertainties, including those
discussed under ''Risk Factors'' in Auxilium's Annual Report on Form 10-K for
the year ended December 31, 2012, filed with the Securities and Exchange
Commission (the "SEC"). While Auxilium may elect to update the forward-looking
statements made in this news release in the future, Auxilium specifically
disclaims any obligation to do so. Auxilium's SEC filings may be accessed
electronically by means of the SEC's home page on the Internet at
http://www.sec.gov. There may be additional risks that Auxilium does not
presently know or that Auxilium currently believes are immaterial which could
also cause actual results to differ from those contained in the
forward-looking statements.

Contacts:
James E. Fickenscher/CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
jfickenscher@auxilium.com

William Q. Sargent Jr./ VP IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
wsargent@auxilium.com

SOURCE Auxilium Pharmaceuticals, Inc.

Website: http://www.auxilium.com
 
Press spacebar to pause and continue. Press esc to stop.